Literature DB >> 17154652

G-protein-coupled receptors and asthma endophenotypes: the cysteinyl leukotriene system in perspective.

Miles D Thompson1, Jun Takasaki, Valérie Capra, G Enrico Rovati, Kathy A Siminovitch, W McIntyre Burnham, Thomas J Hudson, Yohan Bossé, David E C Cole.   

Abstract

Genetic variation in specific G-protein coupled receptors (GPCRs) is associated with a spectrum of respiratory disease predispositions and drug response phenotypes. Although certain GPCR gene variants can be disease-causing through the expression of inactive, overactive, or constitutively active receptor proteins, many more GPCR gene variants confer risk for potentially deleterious endophenotypes. Endophenotypes are traits, such as bronchiole hyperactivity, atopy, and aspirin intolerant asthma, which have a strong genetic component and are risk factors for a variety of more complex outcomes that may include disease states. GPCR genes implicated in asthma endophenotypes include variants of the cysteinyl leukotriene receptors (CYSLTR1 and CYSLTR2), and prostaglandin D2 receptors (PTGDR and CRTH2), thromboxane A2 receptor (TBXA2R), beta2-adrenergic receptor (ADRB2), chemokine receptor 5 (CCR5), and the G protein-coupled receptor associated with asthma (GPRA). This review of the contribution of variability in these genes places the contribution of the cysteinyl leukotriene system to respiratory endophenotypes in perspective. The genetic variant(s) of receptors that are associated with endophenotypes are discussed in the context of the extent to which they contribute to a disease phenotype or altered drug efficacy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17154652     DOI: 10.1007/BF03256212

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  157 in total

Review 1.  Heterogeneity of therapeutic responses in asthma.

Authors:  J M Drazen; E K Silverman; T H Lee
Journal:  Br Med Bull       Date:  2000       Impact factor: 4.291

2.  Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist.

Authors:  J Grossman; I Faiferman; J W Dubb; D J Tompson; W Busse; E Bronsky; A Montanaro; L Southern; D Tinkelman
Journal:  J Asthma       Date:  1997       Impact factor: 2.515

3.  CCR5 Delta32 deletion and atopic asthma in India.

Authors:  J Batra; M Sharma; R Chatterjee; S Sharma; U Mabalirajan; B Ghosh
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

Review 4.  The G protein-coupled receptors: pharmacogenetics and disease.

Authors:  Miles D Thompson; W McIntyre Burnham; David E C Cole
Journal:  Crit Rev Clin Lab Sci       Date:  2005       Impact factor: 6.250

5.  The interaction of class B G protein-coupled receptors with their hormones.

Authors:  F Horn; R Bywater; G Krause; W Kuipers; L Oliveira; A C Paiva; C Sander; G Vriend
Journal:  Receptors Channels       Date:  1998

6.  Genetics of asthma: the University of Toronto Program. University of Toronto Genetics of Asthma Research Group.

Authors:  A S Slutsky; N Zamel
Journal:  Am J Respir Crit Care Med       Date:  1997-10       Impact factor: 21.405

Review 7.  The theory of speciation via the founder principle.

Authors:  A R Templeton
Journal:  Genetics       Date:  1980-04       Impact factor: 4.562

8.  Polymorphisms of the beta2-adrenergic receptor and asthma.

Authors:  S B Liggett
Journal:  Am J Respir Crit Care Med       Date:  1997-10       Impact factor: 21.405

9.  Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population.

Authors:  I Sayers; S Barton; S Rorke; J Sawyer; Q Peng; B Beghé; S Ye; T Keith; J B Clough; J W Holloway; A P Sampson; S T Holgate
Journal:  Clin Exp Allergy       Date:  2003-08       Impact factor: 5.018

10.  Urinary leukotriene E4 after exercise challenge in children with asthma.

Authors:  Y Kikawa; T Miyanomae; Y Inoue; M Saito; A Nakai; Y Shigematsu; S Hosoi; M Sudo
Journal:  J Allergy Clin Immunol       Date:  1992-06       Impact factor: 10.793

View more
  8 in total

Review 1.  Variation in the Serotonin Transporter Gene and Alcoholism: Risk and Response to Pharmacotherapy.

Authors:  Miles D Thompson; George A Kenna
Journal:  Alcohol Alcohol       Date:  2015-08-26       Impact factor: 2.826

2.  Fluorogen activating proteins in flow cytometry for the study of surface molecules and receptors.

Authors:  Matthew J Saunders; Christopher Szent-Gyorgyi; Gregory W Fisher; Jonathan W Jarvik; Marcel P Bruchez; Alan S Waggoner
Journal:  Methods       Date:  2012-02-16       Impact factor: 3.608

3.  Smooth muscle cell arachidonic acid release, migration, and proliferation are markedly attenuated in mice null for calcium-independent phospholipase A2beta.

Authors:  Sung Ho Moon; Christopher M Jenkins; David J Mancuso; John Turk; Richard W Gross
Journal:  J Biol Chem       Date:  2008-10-16       Impact factor: 5.157

4.  Asthma in sickle cell disease: implications for treatment.

Authors:  Kathryn Blake; John Lima
Journal:  Anemia       Date:  2011-03-03

Review 5.  Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association Studies.

Authors:  Miles D Thompson; Valerie Capra; Mark T Clunes; G E Rovati; Jana Stankova; Mary C Maj; David L Duffy
Journal:  Front Pharmacol       Date:  2016-12-01       Impact factor: 5.810

6.  Comprehensive transcriptome analysis of peripheral blood unravels key lncRNAs implicated in ABPA and asthma.

Authors:  Chen Huang; Dongliang Leng; Peiyan Zheng; Min Deng; Lu Li; Ge Wu; Baoqing Sun; Xiaohua Douglas Zhang
Journal:  PeerJ       Date:  2021-06-24       Impact factor: 2.984

7.  Immune and Inflammatory Responses in GERD and Lansoprazole.

Authors:  Hajime Isomoto; Yoshito Nishi; Yusei Kanazawa; Saburo Shikuwa; Yohei Mizuta; Kenichiro Inoue; Shigeru Kohno
Journal:  J Clin Biochem Nutr       Date:  2007-09       Impact factor: 3.114

8.  Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics.

Authors:  Miles D Thompson; Takeshi Sakurai; Innocenzo Rainero; Mary C Maj; Jyrki P Kukkonen
Journal:  Pharmaceuticals (Basel)       Date:  2017-10-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.